The decreasing rates of V_p with temperature. by Nazlı Tunar Özcan (14833635)

“…The V_p and the σ_t of Çankırı rock salt decrease with increasing temperatures of samples whereas the σ_c increases. …”

Effects of s-ketamine and midazolam on respiratory parameters. by Oscar F. C. van den Bosch (22184246)

Flow chart of the study participants. by Oscar F. C. van den Bosch (22184246)

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

Fig 2 - by Nida Mansoora (11648641)

Decreased total protein synthesis in muscle and increased amino acid concentrations in plasma in obese subjects. by Lee Tran (2106961)

Fig 3 - by Nida Mansoora (11648641)

Fig 4 - by Nida Mansoora (11648641)

Fig 1 - by Nida Mansoora (11648641)

CXCL8 (2, 20, and 200 pg/ml) and CCL20 (5, 50, and 500 pg/ml) enhanced Ki-67 gene expression, but only 200 pg/ml of CXCL8 and 500 pg/ml of CCL20 enhanced early osteogenic marker ge... by Janak L. Pathak (759122)

Effects of subchronic exposure to CeO₂-NPs on α-diversity of intestinal microflora in rats(n = 10, ). by Qianru Ye (18078522)

Effect of different treatments on ionic contents like sodium, calcium, potassium, phosphorous and soluble proteins constituents of two wheat genotypes (Markaz 19 and Ujala 16) afte... by Nida Mansoora (11648641)

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)